Veryan

Veryan News

Otsuka Medical Devices Acquires Veryan

14th December 2018

Dublin, Ireland, 14 December, 2018.  Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a 100% subsidiary of Otsuka Holdings Co., Ltd., and Veryan Medical Ltd. (“Veryan”) have announced the completion of the acquisition of Veryan by Otsuka Medical Devices through […]

Read More
Veryan Premarket Approval

Veryan Receives PreMarket Approval

5th October 2018

Horsham, UK. 05 October 2018: Seroba Investee, Veryan Medical Ltd, today announced that the Company has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA).  The device is approved for […]

Read More
Biomimics 3d

Veryan Announces Submission of its PMA Application to the FDA

31st January 2018

1 February 2018: Seroba’s investee company, Veryan Medical, has announced that the Company has submitted a Premarket Approval (PMA) application for the BioMimics 3D Vascular Stent System to the U.S. Food & Drug Administration. Pivotal to the content of the PMA […]

Read More
Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

24th October 2016

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration […]

Read More
Veryan Premarket Approval

Veryan announces first patient enrolment into MIMICS-3D Registry

15th September 2016

MIMICS-3D is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Self-Expanding Stent System in the treatment of peripheral arterial disease. The Registry will evaluate safety, effectiveness and device performance within a real-world clinical population in a minimum of […]

Read More
Veryan News

Veryan Medical Announces Trial Results

13th June 2016

Veryan Medical has announced the achievement of four significant milestones in its MIMICS clinical programme: (1) The publication of the Mimics Study article; (2) The enrolment of the 200th patient in the MIMICS-2 IDE Study; (3) The first live case […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top